Evaluating posaconazole, its pharmacology, efficacy and safety for the prophylaxis and treatment of fungal infections. (22nd January 2022)

• Record Type: Journal Article
• Authors: Panagopoulou, Paraskevi; Roilides, Emmanuel
• Is Part Of: Expert opinion on pharmacotherapy. Volume 23:Number 2(2022)
• Page Start: 175
• Page End: 199
• Publication Date: 2022-01-22
• Subjects: Posaconazole -- invasive fungal diseases -- review -- efficacy -- safety -- azoles -- candidiasis -- aspergillosis -- rare fungi -- therapy -- prophylaxis; Chemotherapy -- Periodicals; 615.5805
• DOI: 10.1080/14656566.2021.1996562
• Languages: English
• ISSNs: 1465-6566

Abstract

ABSTRACT: Introduction: Invasive fungal diseases (IFDs) are a significant cause of morbidity and mortality among immunocompromised patients. Safe and effective antifungal medications used for prophylaxis and treatment are pivotal in their management. Posaconazole is a promising triazole antifungal agent. Areas covered: The authors discuss the pharmacological properties of posaconazole, including pharmacokinetics/pharmacodynamics, safety and tolerability profile, together with efficacy data for prophylaxis and treatment as well as its use in special populations based on current literature. Expert opinion: Posaconazole has a favorable safety and tolerability profile; however, caution is advised when co-administered with agents that are CYP3A4 inhibitors, because their concentration may significantly increase, and their levels should be closely monitored. It has an extended spectrum of activity against yeasts and filamentous fungi. It is successfully used as prophylaxis for patients with acute myeloid leukemia (AML)/myelodysplastic syndrome (MDS) and post-hematopoietic cell transplantation (HCT) with graft-versus-host disease (GVHD). It is the first line treatment for oropharyngeal candidiasis and is also used as a salvage treatment for refractory IFDs. Currently available formulations include the oral suspension, delayed-release tablets and solution for intravenous infusion, all with different PK/PD properties and indications. Its use in children and adolescents is currently being examined in Phase-II clinical trials.